Fig. 4
From: Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Sequential network meta-analyses over A Cardiovascular death or hospitalization for heart failure among DM/non-DM, HF/non-HF, CKD/non-CKD patients B Kidney function progression, AKI for DM/non-DM patients with SGLT2 inhibitors versus placebo. AKI acute kidney injury, CKD Chronic kidney disease, DM Diabetes Mellitus, HF Heart failure, SGLT2 Sodium–Glucose Cotransporter 2